Saladax Biomedical and InsightRX to Present Chemotherapy Drug Results at International Congress in September
SAN FRANCISCO, September 14, 2021 / PRNewswire / – InsightRX, which provides a cloud-based precision assay platform to help guide treatment decisions, today announced its participation with Saladax Biomedical, Inc., at the upcoming 19e International Congress of Therapeutic Drug Surveillance and Clinical Toxicology (IATDMCT) of 19-22 Sep 2021. During the conference, InsightRX and Saladax will present the results of a solution that combines Saladax’s MyCare ™ assay kit with InsightRX’s precision assay technology to individualize Busulfan therapy.
Busulfan is a chemotherapy drug for the treatment of chronic myelogenous leukemia, a type of cancer that starts in hematopoietic cells in the bone marrow. Exposure to busulfan has been associated with veno-occlusive disease (causing considerable morbidity and mortality), disease relapse and transplant failure (a potentially fatal complication of stem cell transplants). Due to these clinical challenges, therapeutic drug monitoring is recommended for busulfan, and drug concentrations are routinely measured to help the clinician choose a dosage regimen that maximizes therapeutic benefit to the patient. It is essential for these measurements that results can be provided in a timely manner so that adjustments can be made in the next dosing cycle.
As part of this partnership, busulfan concentration levels generated by Saladax assay technology are interpreted using the InsightRX precision assay platform to improve achievement of exposure targets while reducing the safety risks for patients receiving the chemotherapy drug.
“For a number of reasons, measuring busulfan is a difficult process,” said Salvatore J. Salamone, PhD, President and CEO of Saladax. “We have created a test that can make it easier for patients to get quick readings of busulfan. Our technology, combined with the InsightRX precision dosing platform, which simplifies manual and highly specialized processes, provides fast and accurate results that will help clinicians select an optimal dose of Busulfan. “
The combination of an automated assay coupled with the InsightRX tool will enable testing and analysis in a clinical routing lab. Centers will no longer have to send samples for analysis, will be able to test in their own facility and will have results in hours instead of days.
“We are proud to partner with Saladax and look forward to presenting the joint solution at an international forum with them,” said Sirj Goswami, PhD, CEO and Co-Founder of InsightRX. “The ability to measure and interpret results accurately can lead to better improvement in care while reducing adverse drug events. This is especially important for life-saving drugs that cause potential side effects, including patient safety and potential harm ”.
In addition to the launch of the combined solution, InsightRX and Saladax will also present several research initiatives at IATDMCT. Saladax will present validation results on the MyCare ™ Oncology Busulfan test kit, which will demonstrate accuracy and precision in over 230 patients. InsightRX will also present its latest contributions to the field of precision dosing with a talk titled: “Boosting Model-Informed Precision Dosing with Machine Learning: Improving Predictions in Atypical Patients”, which highlights how machine learning can be used. to selectively flatten earlier models. during traditional pharmacometric approaches, improving model-based precision dosing in aberrant patients.
Saladax and InsightRX will present their findings at the Rome, Italy. This is the latest foray into Europe for InsightRX, which recently announced it is expanding its presence on the continent with its CE mark, now approved in six countries. Additionally, InsightRX has a commercial contract to use its precision assay platform with an academic medical center in the Netherlands.
About Saladax Biomedical, Inc.
Based at Bethlehem, Pennsylvania, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic levels of drugs for essential and life-saving drugs prescribed by psychiatrists and oncologists. Since 2007, Saladax’s proprietary technology has been used in clinical laboratories and healthcare settings to help clinicians monitor and optimize patient care. Additionally, the company works with leading pharmaceutical companies to develop assays for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
??InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analysis designed to individualize point-of-care treatment. The platform leverages patient-specific data, pharmacological models and machine learning to understand each patient’s unique pharmacological profile and can be seamlessly integrated into a clinical workflow. InsightRX Nova has been CE marked in six European countries, once again demonstrating the company’s commitment to quality, cybersecurity, and general privacy and data protection regulations. Learn more about the recently announced InsightRX $ 10 million Series A financing.
InsightRX media contact
E-mail: [email protected]